Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat Media Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsAuthored by Nathan Reiff. Published: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
Cancer remains one of biotechnology's greatest medical challenges, even as the oncology market is projected to reach $366 billion over the next eight years. Companies often take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms. Several promising treatments have shown significant potential—and with that comes the possibility of substantial sales. Two smaller biotech firms are experiencing notable share price momentum thanks to their leading oncology drugs. Beyond offering promising clinical potential, these therapies could help the companies move beyond penny-stock or otherwise unstable status and toward long-term stability. Still, both firms face meaningful risks, making them typical high-risk, high-reward biotech investments. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle I've worked for the CIA, personally met four US presidents, and spent 45 years studying the markets—calling Black Monday six weeks before it happened, predicting the fall of the Berlin Wall, and pinpointing the exact bottom in 2009. But what I'm about to share with you is the boldest prediction of my career. After meeting Elon Musk face-to-face at a private gathering of Wall Street elites and months of my own research, I'm now staking my reputation on one date: March 26, 2026. That's when I believe Elon will announce the SpaceX IPO—what Bloomberg is calling the biggest listing of all time. I have found an access code that lets you grab a pre-IPO stake before it happens, but in 72 hours, your window could close. Click here to see how to claim your SpaceX access code Iovance Biotherapeutics Inc. (NASDAQ: IOVA) bucked broader market trends in early March, rising nearly 37% in a week when the S&P 500 slipped about 1%. That added to IOVA's year-to-date (YTD) gains, which have more than doubled shares so far. Still, with a consensus price target of $8.88, Wall Street is forecasting additional upside—roughly 71% from current levels. The primary catalyst for Iovance's share movement is Amtagvi, a T-cell immunotherapy for certain melanoma patients. Amtagvi was approved in the United States for melanoma in 2024 and has gained commercial momentum, with additional approvals likely in the E.U., U.K., and other regions. When paired with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could exceed $1 billion in peak U.S. sales. The drug's potential may extend beyond melanoma: Amtagvi has received FDA Fast Track Designation for non-small cell lung cancer and is being investigated for other indications. Some of Iovance's outperformance this year also followed its Q4 2025 earnings report in late February, in which the company reported a smaller-than-expected loss per share and $5 million in revenue. For the full year, revenue rose roughly 30% year-over-year (YOY). Iovance is a small-cap (about $2 billion) biotech and is considered a penny stock; despite this year's rally, analysts remain cautious—about half of its roughly a dozen ratings are Hold or Sell. Significant risks remain beyond the usual biotech caveats. Amtagvi is a personalized therapy that is costly and complex to manufacture, and production challenges could constrain profitability even as demand increases. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but its YTD performance far outpaces Iovance's: IBRX shares are up nearly 300% in 2026 alone. Analysts set a price target of $13.60, implying roughly 70% upside from current levels even after the recent run. ImmunityBio's primary growth driver is Anktiva, a treatment for certain types of bladder cancer. In February, shares jumped after the E.U. regulator granted conditional marketing authorization—the latest in a string of international approvals. Anktiva is rapidly driving revenue growth: the drug generated $113 million in sales last year, a roughly 700% YOY increase. Like Amtagvi, Anktiva is being evaluated for additional cancer indications, which could expand its market opportunity. Despite the dramatic run-up, IBRX remains speculative and risky. The company reported a full-year net loss of $351 million for 2025 as R&D expenses continue to rise. Wall Street appears somewhat more bullish on ImmunityBio than on Iovance: six of seven analysts rate the stock a Buy or equivalent. | 
